NDATOPICALSUSPENSION
Approved
Jan 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
5/8 — Partial
NATROBA (spinosad) by Cipher Pharmaceuticals is insects. First approved in 2011.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NATROBA (spinosad) is a topical pediculicide suspension approved in 2011 for treating head lice and scabies infestations. The active ingredient causes hyperexcitation in insects, leading to paralysis and death. It represents a natural product-derived alternative to synthetic pediculicides.
$0.131MPart D
Peak7.4 years to LOEPeak-stage product with minimal Part D spending suggests niche market positioning; small claims volume indicates specialized sales and medical affairs focus rather than large-scale commercial team expansion.
Mechanism of Action
insects. After periods of hyperexcitation, lice and mites become paralyzed and die.
Pharmacologic Class:
Pediculicide
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies
Started Mar 2022
50 enrolled
Scabies
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
Started May 2017
280 enrolled
Scabies
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
Started May 2017
291 enrolled
Scabies
Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation
Started Sep 2011
26 enrolled
Pediculosis
A Dose Ranging Study of Different Strengths of Spinosad Topical Creme in Subjects With Pediculosis Capitis
Started Mar 2006
120 enrolled
Pediculosis Capitis (Head Lice)
Worked on NATROBA at Cipher Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.